Pharmacokinetics and Toxicity of Tacrolimus Early after Heart and Lung Transplantation

American Journal of Transplantation

Volumn 15, Issue 9, 2015, Pages 2301-2313

  Sikma, M A ^a   Van Maarseveen, E M ^a   Van De Graaf, E A ^a   Kirkels, J H ^a   Verhaar, M C ^a   Donker, D W ^a   Kesecioglu, J ^a   Meulenbelt, J ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

calcineurin inhibitor: tacrolimus; critical care intensive care management; drug toxicity; immunosuppressant; patient safety; pharmacokinetics pharmacodynamics

Indexed keywords

CYTOCHROME P450 3A; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MONITORING; GRAFT RECIPIENT; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE ABSORPTION; LUNG TRANSPLANTATION; NEPHROTOXICITY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; GRAFT REJECTION; HEART LUNG TRANSPLANTATION; HUMAN; METABOLISM; POSTOPERATIVE COMPLICATION; PROGNOSIS; TISSUE DISTRIBUTION;

DRUG MONITORING; GRAFT REJECTION; HEART-LUNG TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; TACROLIMUS; TISSUE DISTRIBUTION;

EID: 84939563828     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13309     Document Type: Review

References (80)

1. Christie JD, Edwards LB, Kucheryavaya AY, et al., The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012; 31: 1073-1086.
2. Wehbe E, Duncan AE, Dar G, Budev M, Stephany B,. Recovery from AKI and short- and long-term outcomes after lung transplatation. Clin J Am Soc Nephrol 2013; 8: 19-25.
3. La Morena De MP, Bravos MDLT, Prado RF, et al., Chronic kidney disease after lung transplantation: Incidence, risk factors, and treatment. Transplant Proc 2010; 42: 3217-3219.
4. Taylor DO, Edwards LB, Aurora P, et al., Registry of the international society for heart and lung transplantation: Twenty-fifth official adult heart transplant report-2008. J Heart Lung Transplant 2008; 27: 943-956.
5. Vicente R, Morales P, Ramos F, Solé A, Mayo M, Villalain C,. Perioperative complications of lung transplantation in patients with emphysema and fibrosis: Experience from 1992-2002. Transplant Proc 2006; 38: 2560-2562.
6. Kaczmarek I, Zaruba M-M, Beiras-Fernandez A, et al., Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results. J Heart Lung Transplant 2013; 32: 277-284.
7. Neurohr C, Huppmann P, Zimmermann G, et al., Tacrolimus and mycophenolate mofetil as first line immunosuppression after lung transplantation. Transpl Int Blackwell Publishing Ltd 2009; 22: 635-643.
8. Griffith BP, Bando K, Hardesty RL, Armitage JM,. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation 1994; 57: 848-851.
9. Treede H, Glanville AR, Klepetko W, et al., Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation. J Heart Lung Transplant 2012; 31: 797-804.
10. Guethoff S, Meiser BM, Groetzner J, et al., Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation. Transplantation 2013; 95: 629-634.
11. Groetzner J, Kur F, Spelsberg F, et al., Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. HEALUN 2004; 23: 632-638.
12. Monchaud C, de Winter BC, Knoop C, et al., Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. Clin Pharmacokinet 2012; 51: 175-186.
13. Phapale PB, Kim S-D, Lee HW, et al., An integrative approach for identifying ametabolic phenotype predictive of individualizedpharmacokinetics of tacrolimus. Clin Pharmacol Ther 2010; 87: 426-436.
14. Undre NA, Meiser BM, Uberfuhr P, et al., Pharmacokinetics of tacrolimus (FK506) in primary orthoropic heart transplant patients. Transplant Proc 1998; 30: 1112-1115.
15. Berge M, Chevalier P, Benammar M, et al., Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis. Ther Drug Monit 2009; 31: 396-399.
16. Saint-Marcoux F, Knoop C, Debord J, et al., Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of bayesian estimators using limited sampling strategies. clinical pharmacokinetics. Clin Pharmacokinet 2005; 44: 1317-1328.
17. Kuypers D,. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 2004; 75: 434-447.
18. Mendonza AE, Zahir H, Gohh RY, Akhlaghi F,. Tacrolimus in diabetic kidney transplant recipients: Pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 2007; 29: 391-398.
19. Maes BD, Lemahieu W, Kuypers D, et al., Differential effect of diarrhea on FK506 versus cyclosporine a trough levels and resultant prevention of allograft rejection in renal transplant recipients. Am J Transplant 2002; 2: 989-992.
20. Bekersky I, Dressler D, Mekki QA,. Effect of low- and high-fat meals on tacrolimus absorption following 5mg single oral doses to healthy human subjects. J Clin Pharmacol 2001; 41: 176-182.
21. Christians U, Jacobsen W, Benet LZ,. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41: 813-851.
22. Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, Sugiyama Y,. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos 2013; 34: 45-78.
23. Christians U, Jacobsen W, Benet LZ, Lampen A,. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41: 813-851.
24. Paine MF, Khalighi M, Fisher JM, Shen DD,. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283: 1-11.
25. Masuda S,. Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients∗1. Clin Pharmacol Ther 2004; 75: 352-361.
26. Goto M, Masuda S, Kiuchi T, et al., CYP3A5∗1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 2004; 14: 471-478.
27. Staatz DCE, Goodman LK, Tett SE,. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin Pharmacokinet 2010; 49: 141-175.
28. Elens L, Capron A, Van Kerckhove VR, et al., 1199G > A and 2677G > T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet Genomics 2007; 17: 873-883.
29. Kroetz DL, Pauli-Magnus C, Hodges LM, et al., Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13: 481-494.
30. Cho JH, Yoon YD, Park JY, et al., Impact of cytochrome P450 3A and ATP-Binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients. Transplant Proc 2012; 44: 109-114.
31. Mancinelli L,. The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups. Clin Pharmacol Ther 2001; 69: 24-31.
32. Press RR, Ploeger BA, Hartigh JD, et al., Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit 2009; 31: 187-197.
33. Barraclough KA, Staatz CE, Johnson DW, et al., Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week. Transpl Int 2012; 25: 1182-1193.
34. Karamperis N, Povlsen JV, Højskov C, Poulsen JH, Pedersen AR, Jørgensen KA,. Comparison of the pharmacokinetics of tacrolimus and cyclosporine at equivalent molecular doses. Transplant Proc 2003; 35: 1314-1318.
35. Jusko WJ, Piekoszewski W, Klintmalm GB,. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57: 281-290.
36. Zahir H, Nand RA, Brown KF, Tattam BN,. Validation of methods to study the distribution and protein binding of tacrolimus in human blood. J Pharmacol Toxicol Methods 2001; 46: 27-35.
37. Fung JJ,. Tacrolimus and transplantation. Transplantation 2004; 77: (Supplement) S41-S43.
38. Wallemacq DPE, Verbeeck RK,. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 2001; 40: 283-295.
39. Chow F-S, Piekoszewski W, Jusko WJ,. Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. Drug Metab Dispos 1997; 25: 610-616.
40. Masuda S,. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin Pharmacol Ther 2000; 68: 98-103.
41. Joy MS, Hogan SL, Thompson BD, Finn WF, Nickeleit V,. Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity. Nephrol Dial Transplant 2007; 22: 1963-1968.
42. Yanagimachi M, Naruto T, Tanoshima R, et al., Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation. Clin Transplant 2010; 24: 855-861.
43. Lamba JK, Lin YS, Thummel K, et al., Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12: 121-132.
44. Hesselink D,. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-254.
45. Elens L, Van Schaik RH, Panin N, et al., Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 2011; 12: 1383-1396.
46. Størset E, Holford N, Hennig S, et al., Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. Br J Clin Pharmacol 2014; 78: 509-523.
47. Gervasini G, Garcia M, Macias RM, Cubero JJ, Caravaca F, Benitez J,. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transpl Int 2012; 25: 471-480.
48. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M,. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391.
49. Hustert E, Haberl M, Burk O, et al., The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-779.
50. Sy SKB, Heuberger J, Shilbayeh S, Conrado DJ, Derendorf H,. A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation. AAPS J 2013; 15: 1189-1199.
51. Moller A, Iwasaki K, Kawamura A, Teramura Y,. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos 1999; 27: 633-636.
52. Shekar K, Roberts JA, Welch S, et al., ASAP ECMO: Antibiotic, sedative and analgesic pharmacokinetics during extracorporeal membrane oxygenation: A multi-centre study to optimise drug therapy during ECMO. BMC Anesthesiol 2012; 12: 29.
53. Van Saet A, de Wildt SN, Knibbe CAJ, Bogers ADJJC, Stolker RJ, Tibboel D,. The effect of adult and pediatric cardiopulmonary bypass on pharmacokinetic and pharmacodynamic parameters. Curr Clin Pharmacol 2013; 8: 297-318.
54. Pea F, Pavan F, Furlanut M,. Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients. Clin Pharmacokinet 2008; 47: 449-462.
55. Textor SC, Wiesner R, Wilson DJ, et al., Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 1993; 55: 1332-1339.
56. De Lima JJ, Xue H, Coburn L, et al., Effects of FK506 in rat and human resistance arteries. Kidney International. Nature Publishing Group 1999; 55: 1518-1527.
57. Bloom RD, Reese PP,. Chronic kidney disease after nonrenal solid-organ transplantation. J Am Soc Nephrol 2007; 18: 3031-3041.
58. Bloom RD, Doyle AM,. Kidney disease after heart and lung transplantation. Am J Transplant 2006; 6: 671-679.
59. Ishani A, Erturk S, Hertz MI, Matas AJ, Savik K, Rosenberg ME,. Predictors of renal function following lung or heart-lung transplantation. Kidney Int 2002; 61: 2228-2234.
60. Stehlik J, Edwards LB, Kucheryavaya AY, et al., The registry of the international society for heart and lung transplantation: 29th official adult heart transplant report-2012. J Heart Lung Transplant 2012; 31: 1052-1064.
61. Lefaucheur C, Nochy D, Amrein C, et al., Renal histopathological lesions after lung transplantation in patients with cystic fibrosis. Am J Transplant 2008; 8: 1901-1910.
62. Omae T, Goto M, Shimomura M, et al., Transient up-regulation of P-glycoprotein reduces tacrolimus absorption after ischemia-reperfusion injury in rat ileum. Biochem Pharmacol 2005; 69: 561-568.
63. Lemahieu W, Maes B, Verbeke K, Rutgeerts P, Geboes K, Vanrenterghem Y,. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant 2005; 5: 1383-1391.
64. Kuypers DR,. Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. Ann Transplant 2008; 13: 11-18.
65. Reams BD, Palmer SM,. Sublingual tacrolimus for immunosuppresion in lung transplantation. Am J Respir Med 2002; 1: 91-98.
66. Knoop C, Thiry P, Saint-Marcoux F, Rousseau A, Marquet P, Estenne M,. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. Am J Transplant 2005; 5: 1477-1482.
67. Jiang T, Acosta D,. An in vitro model of cyclosporine-induced nephrotoxicity. Fundam Appl Toxicol 1993; 20: 486-495.
68. Sharina H, Kek TL, Kwong SJS, et al., Pharmacogenotyping of CYP3A5 in predicting dose-adjusted trough levels of tacrolimus among Malaysian kidney-transplant patients. Br J Clin Pharmacol 2003; 57: 298-309.
69. Otagiri M,. A molecular functional study on the interactions of drugs with plasma. Drug Metab Pharmacokinite 2005; 20: 309-323.
70. Lüthold S, Berneis K, Bady P, Müller B,. Effects of infectious disease on plasma lipids. Eur J Clin Invest 2007; 37: 573-579.
71. Van Leeuwen HJ, Heezius ECJM, Dallinga GM, van Strijp JAG, Verhoef J, van Kessel KPM,. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 2003; 31: 1359-1366.
72. Piekoszewski W, Jusko WJ,. Plasma protein binding of tacrolimus in humans. J Pharm Sci 1993; 82: 340-341.
73. Zsila F,. Overlapping ligand specificity of P-glycoprotein and serum 1-Acid glycoprotein: Evidences and potential implications. Curr Drug Metab 2007; 8: 563-593.
74. Zahir H, McCaughan G, Gleeson M, Nand RA, McLachlan AJ,. Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol 2004; 57: 298-309.
75. Gonschior A-K, Christians U, Winkler M, Linck A, Baumann J, Sewing K-F,. Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. Clin Chem 1996; 42: 1426-1432.
76. Capone D, Gentile A, Imperatore P, Palmiero G, Basile V,. Effects of itraconazole on tacrolimus blood concentrations in a renal transplant recipient. Ann.Pharmacother 1999; 33: 1124-1125.
77. Zahir H, McLachlan AJ, Nelson A, McCaughan G, Gleeson M, Akhlagi F,. Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Ther Drug Monit 2005; 27: 422-430.
78. Staatz C,. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol 2002; 72: 660-669.
79. Rey E, Tréluyer JM, Pons G,. Drug disposition in cystic fibrosis. Clin Pharmacokinet 1998; 35: 314-329.
80. Rifai N, Chao F-F, Pham Q, Thiessen J, S, oldin SJ,. The role of lipoproproteins in the transport and uptake of cyclosporine and dihydro-tacrolimus into HepG2 and JURKAT cell lines. Clin Biochem 2013; 29: 1-7.